ctDNA / Liquid Biopsy Review
Interpretation of circulating tumour DNA results, including their limits.
- Patients with ctDNA results they want interpreted.
- Clinicians assessing whether a ctDNA result should change management.
- ctDNA report, variant allele fractions and assay characteristics
- Concordance with tissue findings where both exist
- Serial results where available
- Interpretation of the findings and their confidence
- An assessment of what a negative or low-level result does and does not exclude
- Monitoring considerations
- Analysis and interpretation are provided to you and, where you wish, directly to your treating team — who continue to prescribe, administer and direct your treatment.
- The work sits alongside your treating oncologist and is designed to strengthen that relationship rather than sit outside it.
- It is built for considered review. Anything acute or time-critical belongs with your treating team or your local emergency service, who can act immediately.
- It sets out what the evidence supports and where it remains uncertain. It does not forecast how a particular cancer will respond.
- ctDNA findings are interpreted alongside imaging and tissue pathology, which answer different questions and remain necessary.
Getting started
Nothing is charged for an enquiry, and scope is agreed in writing before any work starts.
Enquiries begin with a short message describing the situation and the question. From there, the documentation needed is agreed, and a scope and timeline are confirmed before any work starts.
The document checklist sets out what is typically needed. Missing items are worth identifying at the outset rather than mid-review.